Cancer Lett. 2019 Jan 17. pii: S0304-3835(19)30023-0. doi: 10.1016/j.canlet.2019.01.011.
[Epub ahead of print]
Jeong S1, Yun HK2, Jeong YA2, Jo MJ2, Kang SH3, Kim JL1, Kim DY2, Park SH2, Kim BR1, Na YJ2, Lee SI3, Kim HD4, Kim DH4, Oh SC5, Lee DH6.
Abstract
Cannabidiol (CBD), one of the compounds present in the marijuana plant, has anti-tumor properties, but its mechanism is not well known. This study aimed to evaluate the apoptotic action of CBD in colorectal cancer (CRC) cells, and focused on its effects on the novel pro-apoptotic Noxa-reactive oxygen species (ROS) signaling pathway. CBD experiments were performed using the CRC cell lines HCT116 and DLD-1. CBD induced apoptosis by regulating many pro- and anti-apoptotic proteins, of which Noxa showed significantly higher expression. To understand the relationship between Noxa and CBD-induced apoptosis, Noxa levels were downregulated using siRNA, and the expression of apoptosis markers decreased. After ROS production was blocked, the level of Noxa also decreased, suggesting that ROS is involved in the regulation of Noxa, which along with ROS is a well-known pro-apoptotic signaling agents. As a result, CBD induced apoptosis in a Noxa-and-ROS-dependent manner. Taken together, the results obtained in this study re-demonstrated the effects of CBD treatment in vivo, thus confirming its role as a novel, reliable anticancer drug.
Copyright © 2019. Published by Elsevier B.V.
KEYWORDS:
Bcl-2 protein family; Marijuana extract; ROS; apoptotic cell death; colon cancer
- PMID: 30660647
- DOI: 10.1016/j.canlet.2019.01.011